MCID: HMN047
MIFTS: 53

Human Cytomegalovirus Infection

Categories: Infectious diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Human Cytomegalovirus Infection

MalaCards integrated aliases for Human Cytomegalovirus Infection:

Name: Human Cytomegalovirus Infection 11 14
Cytomegalovirus Infection 28 2 16
Cytomegalovirus Infections 41 71

Classifications:



External Ids:

Disease Ontology 11 DOID:0080827
UMLS 71 C0010823

Summaries for Human Cytomegalovirus Infection

MedlinePlus: 41 Cytomegalovirus (CMV) is a virus found around the world. It is related to the viruses that cause chickenpox and infectious mononucleosis (mono). Between 50% and 80% of adults in the United States have had a CMV infection by age 40. Once CMV is in a person's body, it stays there for life. CMV is spread through close contact with body fluids. Most people with CMV don't get sick and don't know that they've been infected. But infection with the virus can be serious in babies and people with weak immune systems. If a woman gets CMV when she is pregnant, she can pass it on to her baby. Usually the babies do not have health problems. But some babies can develop lifelong disabilities. A blood test can tell whether a person has ever been infected with CMV. Most people with CMV don't need treatment. If you have a weakened immune system, your doctor may prescribe antiviral medicine. Good hygiene, including proper hand washing, may help prevent infections. Centers for Disease Control and Prevention

MalaCards based summary: Human Cytomegalovirus Infection, also known as cytomegalovirus infection, is related to toxoplasmosis and colitis, and has symptoms including fever and pruritus. An important gene associated with Human Cytomegalovirus Infection is PML (PML Nuclear Body Scaffold), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Prednisone and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and kidney, and related phenotypes are nervous system and no phenotypic analysis

CDC: 2 Cytomegalovirus (pronounced sy-toe-MEG-a-low-vy-rus), or CMV, is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. When a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. About one out of every 200 babies is born with congenital CMV infection. About one in five babies with congenital CMV infection will have long-term health problems.

Disease Ontology: 11 A viral infectious disease that has material basis in Human betaherpesvirus 5.

Related Diseases for Human Cytomegalovirus Infection

Diseases related to Human Cytomegalovirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1464)
# Related Disease Score Top Affiliating Genes
1 toxoplasmosis 31.2 TNF IL6 IL17A
2 colitis 31.1 TNF IL6 IL17A CD4 CCR6
3 chorioretinitis 30.9 TNF IL6 IL17A CD8A CD4 CCR6
4 gastritis 30.9 TNF IL6 IL17A CCR6
5 esophagitis 30.8 TNF IL6 EGFR
6 bronchiolitis 30.8 TNF IL6 IL17A
7 bronchiolitis obliterans 30.8 TNF IL6 IL17A
8 rubella 30.8 TNF IL6 IFNB1
9 adult t-cell leukemia/lymphoma 30.7 CD8A CD4 CCR6
10 cystitis 30.7 TNF IL6 IL17A
11 encephalitis 30.7 TNF RSAD2 IL6 IFNB1
12 bilirubin metabolic disorder 30.7 TNF IL6 CD8A CD4
13 pneumocystosis 30.6 TNF IL6 IL17A CD8A CD4 CCR6
14 congenital toxoplasmosis 30.6 TNF CD8A CD4
15 deficiency anemia 30.6 TNF IL6 CD8A CD4 CCR6
16 purpura 30.6 TNF IL6 IL17A
17 granulomatous hepatitis 30.6 TNF CD8A CD4
18 pericardial effusion 30.5 TNF IL6 CD4
19 hemophagocytic lymphohistiocytosis 30.5 TNF IL6 CD8A CD4 CCR6
20 perinatal necrotizing enterocolitis 30.5 TNF IL6 IL17A CD4 CCR6
21 arteries, anomalies of 30.5 TNF MIR199A1 IL6 CCR6
22 diarrhea 30.5 TNF IL6 IFNB1 EGFR
23 intestinal perforation 30.5 TNF IL6 CD8A CD4 CCR6
24 sialadenitis 30.5 TNF CD4 CCR6
25 herpes simplex 30.5 RSAD2 PML IFNB1 GYPC CD8A
26 exanthem 30.5 TNF IL6 IL17A EGFR CD8A CD4
27 anemia, autoimmune hemolytic 30.5 IL6 CD8A CD4 CCR6
28 thrombocytopenia due to platelet alloimmunization 30.4 CD8A CD4 CCR6
29 thrombocytopenic purpura, autoimmune 30.4 CD8A CD4 CCR6
30 vascular disease 30.4 TNF MIR199A1 MAPK1 IL6 CCR6
31 combined immunodeficiency 30.4 TNF IL6 IL17A CD8A CD4 CCR6
32 pharyngitis 30.4 TNF IL6 CD8A CD4 CCR6
33 duodenitis 30.4 TNF CD8A CD4
34 ileus 30.4 TNF IL6 IL17A
35 legionnaire disease 30.4 TNF IL6 CD4
36 hemorrhagic cystitis 30.4 TNF IL6 CD8A CD4
37 demyelinating polyneuropathy 30.4 TNF IL6 CD8A CD4
38 viral infectious disease 30.4 TNF MIR199A1 IL6 IL17A IFNB1 CD4
39 adult-onset still's disease 30.4 TNF IL6 CCR6
40 cryptosporidiosis 30.3 TNF CD8A CD4
41 portal hypertension 30.3 TNF MIR199A1 CCR6
42 aortic aneurysm, familial abdominal, 1 30.3 TNF MIR199A1 IL6 CCR6
43 pneumonia 30.3 TNF IL6 IL17A CD8A
44 syphilis 30.3 TNF IL17A CD8A CD4 CCR6
45 henoch-schoenlein purpura 30.3 TNF IL6 CD4 CCR6
46 inflammatory bowel disease 1 30.3 TNF IL6 IL17A CCR6
47 histiocytosis 30.3 TNF IL17A CCR6
48 chlamydia 30.3 TNF IL6 IL17A
49 dermatitis 30.3 TNF IL6 IL17A CCR6
50 juvenile rheumatoid arthritis 30.3 TNF IL6 CD4 CCR6

Comorbidity relations with Human Cytomegalovirus Infection via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Human Cytomegalovirus Infection:



Diseases related to Human Cytomegalovirus Infection

Symptoms & Phenotypes for Human Cytomegalovirus Infection

UMLS symptoms related to Human Cytomegalovirus Infection:


fever; pruritus

MGI Mouse Phenotypes related to Human Cytomegalovirus Infection:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.93 B3GAT1 CCR6 CD4 CD8A EGFR HLA-E
2 no phenotypic analysis MP:0003012 9.91 CD4 EGFR HLA-E IFNB1 IL17A KLRD1
3 immune system MP:0005387 9.83 CCR6 CD4 CD8A EGFR HLA-E IFNB1
4 hematopoietic system MP:0005397 9.5 CCR6 CD4 CD8A EGFR GYPC HLA-E

Drugs & Therapeutics for Human Cytomegalovirus Infection

Drugs for Human Cytomegalovirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Basiliximab Approved, Investigational Phase 4 179045-86-4
6
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
7
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
8
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
9
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
10
Metamizole Approved, Investigational, Withdrawn Phase 4 50567-35-6 3111 522325
11
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
12
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
13
Letermovir Approved, Investigational Phase 4 917389-32-3 9916099 45138674
14
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
15
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
16
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
17
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
18
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
19
Valaciclovir Approved, Investigational Phase 4 124832-27-5, 124832-26-4 60773 135398742
20
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
21 Ophthalmic Solutions Phase 4
22 Antifungal Agents Phase 4
23 Hormones Phase 4
24 Hormone Antagonists Phase 4
25 Calcineurin Inhibitors Phase 4
26 Hydrocortisone 17-butyrate 21-propionate Phase 4
27 Gastrointestinal Agents Phase 4
28 Antineoplastic Agents, Hormonal Phase 4
29 Antiemetics Phase 4
30 Protective Agents Phase 4
31 Neuroprotective Agents Phase 4
32 Calcium, Dietary Phase 4
33 Anesthetics Phase 4
34 Anticonvulsants Phase 4
35 Tocolytic Agents Phase 4
36 Analgesics Phase 4
37 calcium channel blockers Phase 4
38 Anti-Arrhythmia Agents Phase 4
39 Reverse Transcriptase Inhibitors Phase 4
40 Poly(ADP-ribose) Polymerase Inhibitors Phase 4
41 Immunologic Factors Phase 4
42 Immunosuppressive Agents Phase 4
43 Antibiotics, Antitubercular Phase 4
44 Anti-Bacterial Agents Phase 4
45 Antitubercular Agents Phase 4
46 Thymoglobulin Phase 4
47 Antilymphocyte Serum Phase 4
48
Triamcinolone hexacetonide Phase 4
49
Triamcinolone diacetate Phase 4
50
Triamcinolone Acetonide Phase 4 6436

Interventional clinical trials:

(show top 50) (show all 300)
# Name Status NCT ID Phase Drugs
1 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus) Unknown status NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
2 Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Unknown status NCT02943057 Phase 4 2% guttae ganciclovir
3 An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients. Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
4 The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
5 Phase IV.II Pilot Study of Treatment of Cytomegalovirus Infection With a Brief Induction With Ganciclovir i.v. Followed by Valganciclovir Oral in Solid Organ Transplant Patients. Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
6 Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
7 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients Completed NCT01552369 Phase 4 Valganciclovir
8 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
9 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus
10 A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®). Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
11 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
12 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
13 Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
14 A Randomized, Open-label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
15 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
16 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
17 A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir Vs. Concurrent Untreated Matched Controls Completed NCT01663740 Phase 4 Valganciclovir
18 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for CMV Infection Completed NCT01509404 Phase 4 Valganciclovir
19 A Prospective Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection According to Baseline hCMV-specific T-cell Response in Kidney Transplant Patients (RESPECT) Completed NCT02550639 Phase 4
20 Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study) Completed NCT00461695 Phase 4
21 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir : Prospective Multicenter Nonrandomized Trial Completed NCT01651585 Phase 4 Valacyclovir arrow
22 Phase IV Clinical Trial, Open, Randomized, Controlled and Multicentric, With Two Parallel Groups, to Assess the Efficacy of a Preventive Strategy Against Cytomegalovirus Infection in Heart Transplant Patients, Based on the Specific Basal T Cell Response Against Cytomegalovirus: ELISPOT-TC Recruiting NCT04278547 Phase 4
23 Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
24 Evaluation of the Tolerability and Clinical Effectiveness of Letermovir in Heart Transplantation Active, not recruiting NCT04904614 Phase 4 Letermovir
25 Effect of the Introduction of mTor Inhibitors in the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response to Control Viral Replication in Kidney Transplant Patients Not yet recruiting NCT04936971 Phase 4 Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm
26 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir: Prospective Multicenter Randomized Trial Versus Placebo Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
27 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
28 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Withdrawn NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
29 Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
30 Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection Unknown status NCT02787382 Phase 3
31 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) Completed NCT01376778 Phase 3 CMV hyperimmune globulin
32 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
33 A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir
34 Participation of Cytomegalovirus Infection or an Autoimmune Process in T Lymphocyte Activation of HIV-1 Infected Patients With Undetectable Viral Load on Antiretroviral Therapy. Completed NCT04067869 Phase 3
35 A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112) Completed NCT00466817 Phase 3 Valganciclovir
36 A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation. Completed NCT00275665 Phase 3 Valganciclovir
37 A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT) Completed NCT03930615 Phase 3 Letermovir;Placebo
38 A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant Completed NCT01077908 Phase 3 Best available antiviral drug therapy
39 Prevention of Human Cytomegalovirus (HCMV) Mother-to-fetus Transmission by Administration of Virus-specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
40 The Leiden CONCERT Study 2.0 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Non-Randomized Trial With Historical Control Group Completed NCT02005822 Phase 3 Valganciclovir
41 Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy Completed NCT02351102 Phase 2, Phase 3 Valacyclovir;Placebo
42 A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants. Completed NCT00411645 Phase 3 maribavir
43 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients Completed NCT00294515 Phase 3 Valganciclovir
44 A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation Completed NCT00227370 Phase 3 valganciclovir
45 A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. Completed NCT00001100 Phase 3 ganciclovir
46 A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration Completed NCT00372229 Phase 3 Valganciclovir CMV Prophylaxis;Valganciclovir (Pre-emptive CMV Therapy);Ganciclovir
47 Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
48 Transfusion-Transmitted Cytomegalovirus Prevention in Neonates Completed NCT00000584 Phase 3 immunoglobulins
49 A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants Completed NCT00497796 Phase 3 maribavir;ganciclovir
50 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir

Search NIH Clinical Center for Human Cytomegalovirus Infection

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cidofovir
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Cytomegalovirus Pyrophosphate Analog DNA Polymerase Inhibitor [EPC]
Foscarnet
Foscarnet Sodium Hexahydrate
Ganciclovir
Ganciclovir Sodium
Immunoglobulins, Intravenous
valganciclovir
Valganciclovir hydrochloride

Genetic Tests for Human Cytomegalovirus Infection

Genetic tests related to Human Cytomegalovirus Infection:

# Genetic test Affiliating Genes
1 Cytomegalovirus Infection 28

Anatomical Context for Human Cytomegalovirus Infection

Organs/tissues related to Human Cytomegalovirus Infection:

MalaCards : T Cells, Bone Marrow, Kidney, Liver, Heart, Lung, Bone

Publications for Human Cytomegalovirus Infection

Articles related to Human Cytomegalovirus Infection:

(show top 50) (show all 10143)
# Title Authors PMID Year
1
Promyelocytic Leukemia Protein Potently Restricts Human Cytomegalovirus Infection in Endothelial Cells. 62 41
36233232 2022
2
Association between active cytomegalovirus infection and lung fibroproliferation in adult patients with acute respiratory distress syndrome: a retrospective study. 62 41
36241980 2022
3
CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 Course. 41
36232655 2022
4
Neurological evaluation of microcephalic children with Zika syndrome and congenital cytomegalovirus infection. 62
36164338 2022
5
MORC3 restricts human cytomegalovirus infection by suppressing the major immediate-early promoter activity. 62
35879101 2022
6
Audiovestibular Consequences of Congenital Cytomegalovirus Infection: Greater Vulnerability of the Vestibular Part of the Inner Ear. 62
35687026 2022
7
Impact of cytomegalovirus infection prior to hematopoietic stem cell transplantation in children with inborn errors of immunity. 62
36102997 2022
8
Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation. 62
36054234 2022
9
Absolute Lymphocyte Count as a Marker for Cytomegalovirus Infection After Heart Transplantation. 62
36228318 2022
10
[Congenital cytomegalovirus infection, is more prevalent in our country in newborns exposed to HIV?] 62
35841598 2022
11
RNA-Seq of amniotic fluid cell-free RNA: a discovery phase study of the pathophysiology of congenital cytomegalovirus infection. 62
35609640 2022
12
Gastric outlet obstruction due to cytomegalovirus infection in an immunocompetent child. 62
36201095 2022
13
Cytomegalovirus infection disrupts the influence of short-chain fatty acid producers on Treg/Th17 balance. 62
36210471 2022
14
Risk factors for cytomegalovirus infection and disease after kidney transplantation: A meta-analysis. 62
35901951 2022
15
Maternal high-dose valacyclovir and its correlation with newborn blood viral load and outcome in congenital cytomegalovirus infection. 62
33143511 2022
16
Congenital cytomegalovirus infection diagnostics and management. 62
35984001 2022
17
Intra-host diversity of drug-resistant cytomegalovirus: A case report of cytomegalovirus infection after allogeneic hematopoietic cell transplantation. 62
35810104 2022
18
Describing the Impact of Maternal Hyperimmune Globulin and Valacyclovir on the Outcomes of Cytomegalovirus Infection in Pregnancy: A Systematic Review. 62
35438780 2022
19
Severe gastritis in a patient treated with immunotherapy: immune-mediated or reactivation of cytomegalovirus? 62
36205315 2022
20
The immune factors driving DNA methylation variation in human blood. 62
36202838 2022
21
[Cytomegalovirus screening during pregnancy : an ongoing debate still in 2022]. 62
36259702 2022
22
Inferring differential subcellular localisation in comparative spatial proteomics using BANDLE. 62
36216816 2022
23
Impact of induction therapy on cytomegalovirus infection and post-transplant outcomes in pediatric heart transplant recipients receiving routine antiviral prophylaxis. 62
36259556 2022
24
Acute cytomegalovirus infection modulates the intestinal microbiota and targets intestinal epithelial cells. 62
36250419 2022
25
The epidemiology and disease burden of congenital TORCH infections among hospitalized children in China: A national cross-sectional study. 62
36240247 2022
26
Retinopathy of Prematurity and Possible Relation Between Postnatal Cytomegalovirus Infection. 62
35441956 2022
27
[Analysis of risk factors and prognosis of cytomegalovirus infection post umbilical cord blood stem cell transplantation in children with primary immunodeficiency diseases]. 62
36207848 2022
28
Good Long-Term Outcome Following Liver Transplant in a Patient With Common Variable Immunodeficiency Syndrome Despite Multiple Infections and Recurrent Nodular Regenerative Hyperplasia. 62
36259616 2022
29
Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression. 62
35709902 2022
30
The association between congenital cytomegalovirus infection and cerebral palsy: A systematic review and meta-analysis. 62
36250689 2022
31
Postchemotherapy immune status in infants with acute lymphoblastic leukemia: A report from the JPLSG MLL-10 trial. 62
35796397 2022
32
[Intestinal pseudo-obstruction: An infrequent manifestation of cytomegalovirus infection]. 62
36253305 2022
33
Brainstem auditory pathway maturation in term neonates with congenital cytomegalovirus infection: a cohort study. 62
36207473 2022
34
Integration of UPLC-QE-MS/MS and network pharmacology to investigate the active components and action mechanisms of tea cake extract for treating cough. 62
35781817 2022
35
A systematic review and meta-analysis of the prevalence of human cytomegalovirus shedding in seropositive pregnant women. 62
36196755 2022
36
Current state of clinical trials regarding lung transplant rejection. 62
35842078 2022
37
Mouse Models for Cytomegalovirus Infections in Newborns and Adults. 62
36083111 2022
38
Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. 62
34864943 2022
39
Exposure to heat stress causes downregulation of immune response genes and weakens the disease resistance of Micropterus salmoides. 62
35839613 2022
40
Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: A single-center retrospective analysis. 62
35725529 2022
41
Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United States. 62
36126024 2022
42
Cytomegalovirus infection in patients with malignant lymphomas who have not received hematopoietic stem cell transplantation. 62
36050665 2022
43
Role of PARP-1 in Human Cytomegalovirus Infection and Functional Partners Encoded by This Virus. 62
36146855 2022
44
Everolimus Use in Lung Transplant Recipients. 62
36192210 2022
45
Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial. 62
36050712 2022
46
Romiplostim use in pregnant women with immune thrombocytopenia. 62
36156812 2022
47
Prenatal infection and schizophrenia: A decade of further progress. 62
34016508 2022
48
Risk factors and incidence of cytomegalovirus viremia and disease in pediatric patients with allogeneic hematopoietic stem cell transplantation: An 8-year single-center experience in Latin America. 62
35647735 2022
49
Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open-Label, Single-Dose, Parallel Group Study. 62
36089648 2022
50
Universal first-trimester cytomegalovirus screening and valaciclovir prophylaxis in pregnant persons: a cost-effectiveness analysis. 62
35714861 2022

Variations for Human Cytomegalovirus Infection

Expression for Human Cytomegalovirus Infection

Search GEO for disease gene expression data for Human Cytomegalovirus Infection.

Pathways for Human Cytomegalovirus Infection

Pathways related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 CCR6 CD4 CD8A HLA-E IFNB1 IL17A
2
Show member pathways
13.58 TNF MAPK1 IL6 IL17A IFNB1 EGFR
3
Show member pathways
13.24 CCR6 CD4 EGFR IL17A IL6 MAPK1
4
Show member pathways
13.23 TNF RSAD2 PML MAPK1 IL6 IL17A
5
Show member pathways
12.61 TNF PML MAPK1 EGFR CD4
6
Show member pathways
12.53 TNF MAPK1 IL6 IL17A EGFR CD4
7 12.51 CD8A IL17A LILRB1 RSAD2 TNF
8
Show member pathways
12.46 TNF MAPK1 IL6 IFNB1
9
Show member pathways
12.23 TNF MAPK1 IL6 IL17A
10 12.14 TNF MAPK1 IL6 EGFR
11
Show member pathways
12.11 TNF RSAD2 PML MAPK1 IL6 IL17A
12
Show member pathways
12.07 HLA-E KLRC1 KLRC2 KLRD1 MAPK1 TNF
13 12 CD8A HLA-E KLRC1 KLRD1 LILRB1
14
Show member pathways
11.98 TNF MAPK1 IL17A IFNB1 CD8A CD4
15 11.95 TNF MAPK1 IL6 EGFR
16
Show member pathways
11.87 TNF IL6 IL17A CD4
17
Show member pathways
11.81 IL6 IL17A CD4
18
Show member pathways
11.74 IL6 IFNB1 CD8A CD4
19 11.71 CD4 IL6 MAPK1
20 11.71 IFNB1 IL6 TNF
21
Show member pathways
11.7 HLA-E KLRC2 KLRD1
22 11.7 TNF KLRC2 KLRC1 IL6 CD8A CD4
23 11.68 CD4 IL17A IL6 MAPK1
24 11.67 TNF IL6 IFNB1 CD8A CD4
25
Show member pathways
11.62 TNF MAPK1 IL6
26 11.61 TNF MIR199A1 IL6
27 11.55 TNF MAPK1 HLA-E CD4
28 11.51 TNF MAPK1 IL6
29 11.41 TNF IL6 IFNB1
30 11.4 MAPK1 KLRD1 KLRC1 HLA-E
31 11.27 TNF IL6 IL17A
32 11.2 TNF IL6 IL17A
33 11.2 TNF IL6 IFNB1 CD4
34 11.1 TNF MAPK1 IFNB1
35 11 TNF KLRD1 IL17A CD8A CD4 CCR6
36 10.97 TNF MAPK1 IL6 IL17A EGFR
37
Show member pathways
10.32 TNF IL6

GO Terms for Human Cytomegalovirus Infection

Cellular components related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.33 B3GAT1 CCR6 CD4 CD8A EGFR GYPC
2 membrane GO:0016021 10.33 B3GAT1 CCR6 CD4 CD8A EGFR GYPC
3 plasma membrane GO:0005886 10.09 CCR6 CD4 CD8A EGFR GYPC KLRC1
4 plasma membrane GO:0005887 10.09 CCR6 CD4 CD8A EGFR GYPC KLRC1
5 receptor complex GO:0043235 9.96 KLRD1 KLRC2 KLRC1 EGFR CD8A
6 external side of plasma membrane GO:0009897 9.6 TNF LILRB1 KLRD1 KLRC2 KLRC1 IL17A

Biological processes related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.29 HLA-E IL17A KLRC1 KLRC2 KLRD1 PML
2 immune response GO:0006955 10.21 CCR6 CD4 CD8A HLA-E IL17A IL6
3 cell surface receptor signaling pathway GO:0007166 10.17 MAPK1 KLRD1 KLRC1 IFNB1 EGFR CD8A
4 defense response to Gram-positive bacterium GO:0050830 10.15 TNF IL6 IL17A HLA-E
5 defense response to virus GO:0051607 10.13 RSAD2 PML LILRB1 IL6 IFNB1
6 response to virus GO:0009615 10.08 TNF RSAD2 LILRB1 IFNB1
7 negative regulation of viral genome replication GO:0045071 10.04 TNF RSAD2 IFNB1
8 humoral immune response GO:0006959 10.01 TNF IL6 IFNB1 CCR6
9 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.97 TNF IL6 IL17A
10 positive regulation of natural killer cell mediated cytotoxicity GO:0045954 9.95 KLRD1 KLRC2 HLA-E
11 adaptive immune response GO:0002250 9.89 LILRB1 KLRD1 KLRC2 KLRC1 IL17A IFNB1
12 immune system process GO:0002376 9.81 RSAD2 PML KLRD1 KLRC2 KLRC1 IL17A
13 negative regulation of T cell mediated cytotoxicity GO:0001915 9.77 LILRB1 KLRD1 KLRC1
14 natural killer cell mediated immunity GO:0002228 9.76 KLRD1 KLRC2
15 negative regulation of cytokine production involved in immune response GO:0002719 9.73 TNF LILRB1
16 regulation of natural killer cell activation GO:0032814 9.73 KLRC1 KLRC2 KLRD1
17 negative regulation of natural killer cell mediated cytotoxicity GO:0045953 9.17 LILRB1 KLRD1 KLRC1 HLA-E

Molecular functions related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 10.02 KLRD1 KLRC2 KLRC1 EGFR CD4
2 MHC class I protein binding GO:0042288 9.65 LILRB1 HLA-E CD8A
3 HLA-E specific inhibitory MHC class Ib receptor activity GO:0062082 9.46 KLRD1 KLRC1
4 protein antigen binding GO:1990405 9.35 KLRD1 KLRC2 KLRC1
5 MHC class I protein complex binding GO:0023024 9.23 KLRD1 KLRC2 KLRC1 CD8A

Sources for Human Cytomegalovirus Infection

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....